{"id":9083,"date":"2026-04-16T14:54:48","date_gmt":"2026-04-16T12:54:48","guid":{"rendered":"https:\/\/www.quinta.cz\/?p=9083"},"modified":"2026-04-16T14:54:48","modified_gmt":"2026-04-16T12:54:48","slug":"quinta-completes-gcc-inspection","status":"publish","type":"post","link":"https:\/\/www.quinta.cz\/cs\/2026\/04\/16\/quinta-completes-gcc-inspection\/","title":{"rendered":"Expanding Beyond FDA &#038; EMA: Strengthening Our Global Regulatory Footprint with GCC"},"content":{"rendered":"<p>We have successfully completed a Good Clinical Practice (GCP) inspection within the Gulf Cooperation Council (GCC) framework through a full on-site inspection, further validating the robustness and transparency of our processes.<\/p>\n<p>The GCC brings together six countries: <strong>Saudi Arabia Sultanate, United Arab Emirates Kingdom, Qatar, Kuwait, Bahrain Kingdom, and Oman<\/strong> \u2014 a fast-growing and strategically important region for innovative therapies.<\/p>\n<p>We are among a limited number GCC-recognized <a href=\"https:\/\/www.quinta.cz\/clinical-testing\/\">bioequivalence (BE) centers<\/a>. Together with our regular inspections by the <a href=\"https:\/\/www.quinta.cz\/2025\/09\/08\/fda-inspections-quinta-analytica-2025\/\">US FDA and EMA<\/a>, this further strengthens our international regulatory foundation and highlights the consistent quality of our clinical research standards.<\/p>\n<p>With this solid international track record, we are well positioned to support partners in navigating complex approval pathways and bringing new treatments to patients across the Middle East and beyond.<\/p>\n<p>We look forward to building new collaborations and continuing to advance global healthcare innovation.<\/p>\n<hr \/>\n<p style=\"text-align: center;\"><strong>Would you like to know more?\u00a0<a href=\"https:\/\/www.quinta.cz\/contact\/\">Let us know<\/a>.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Quinta-Analytica has successfully completed a full on-site GCP inspection within the GCC framework, further strengthening its international regulatory footprint and clinical research credibility.<\/p>\n","protected":false},"author":5,"featured_media":9085,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[28,27],"class_list":["post-9083","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorised","tag-gcc","tag-gcp"],"_links":{"self":[{"href":"https:\/\/www.quinta.cz\/cs\/wp-json\/wp\/v2\/posts\/9083","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.quinta.cz\/cs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.quinta.cz\/cs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.quinta.cz\/cs\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.quinta.cz\/cs\/wp-json\/wp\/v2\/comments?post=9083"}],"version-history":[{"count":1,"href":"https:\/\/www.quinta.cz\/cs\/wp-json\/wp\/v2\/posts\/9083\/revisions"}],"predecessor-version":[{"id":9084,"href":"https:\/\/www.quinta.cz\/cs\/wp-json\/wp\/v2\/posts\/9083\/revisions\/9084"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.quinta.cz\/cs\/wp-json\/wp\/v2\/media\/9085"}],"wp:attachment":[{"href":"https:\/\/www.quinta.cz\/cs\/wp-json\/wp\/v2\/media?parent=9083"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.quinta.cz\/cs\/wp-json\/wp\/v2\/categories?post=9083"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.quinta.cz\/cs\/wp-json\/wp\/v2\/tags?post=9083"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}